Posts Tagged ‘novel’
China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) (“China Aoxing”), a pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it completed Phase II clinical study for oral TJSL capsules, a novel investigational drug to treat primary dysmenorrhea (“PD”) , or menstrual pain, in adult women…
Novel Intranasal Nanoemulsion Vaccine Adjuvant Also Effective By Subcutaneous And Intramuscular Injection
NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections…
Visionary approach to improving eyesight: Novel scleral lens proves clinically beneficial
Joseph Balboni loves sports. An avid tennis player and golfer, as well as baseball fan, the 46-year-old insurance agent became increasingly frustrated over time as his eyesight dimmed due to keratoconus, a degenerative eye disorder. Unable to return the tennis ball or see the pitch at Red Sox games, he faced the prospect of a corneal transplant to restore his vision and eye comfort.
Abbott To Acquire Novel Investigational Biologic To Treat Chronic Pain
Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV’s PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company’s pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.
Novel H1N1 Influenza Is Widespread In Alabama; Health Care System Is Handling It Well
The novel H1N1 virus remains the dominant virus in Alabama, with more than 99 percent of the recently circulating influenza viruses confirmed as that strain. The frequency of disease shows that there has been a dramatic increase in people presenting with H1N1 influenza, with the percent of people with influenza-like symptoms seen in doctors’ offices increasing from less than 1 percent on July 25 to almost 8 percent on Aug. 29.
Second Alabama Child Dies From Novel H1N1 Influenza
The Alabama Department of Public Health has been informed that a school-age child from Jackson County has died from influenza. It is presumed that novel H1N1 influenza is the likely cause of death because of its prevalence in Alabama. This would be the third known death in the state from novel H1N1 influenza. This death serves as reminder of the need for everyone to take additional precautions because of the early onset of influenza in Alabama.
Novel, Orally Inhaled Migraine Therapy Is Effective, Study Shows
A new study shows an investigational, orally-inhaled therapy is effective in treating migraines. The multi-center, phase three FREEDOM-301 trial for the orally-inhaled migraine therapy, LEVADEX, shows study participants had significant relief from symptoms such as pain, nausea and light and sound sensitivity when compared to placebo treatment.
NuPathe Reports Positive Phase III Results For Zelrix, A Novel Transdermal Patch For Acute Migraine
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced top-line results from the pivotal Phase III clinical trial of Zelrix?, a novel transdermal patch in clinical development for the treatment of acute migraine.
Novel, Orally Inhaled Migraine Therapy Found To Be Effective
A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines. The multi-center, phase three FREEDOM-301 trial for the orally-inhaled migraine therapy, LEVADEX?, shows study participants had significant relief from symptoms such as pain, nausea and light and sound sensitivity when compared to placebo treatment.
Novel H1N1 Influenza A (Swine Flu) Update For Arkansans
As of Wednesday, July 29, the Arkansas Department of Health (ADH) reported 150 lab-confirmed cases of novel H1N1 influenza A (Swine Flu) in Arkansas in residents from 38 of the state’s 75 counties. There have been no deaths due to H1N1 influenza A in Arkansas.
Rx Drug Compare
Translator
By N2H